<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28075066</article-id><article-id pub-id-type="pmc">5412676</article-id><article-id pub-id-type="doi">10.1111/dom.12875</article-id><article-id pub-id-type="publisher-id">DOM12875</article-id><article-categories><subj-group subj-group-type="overline"><subject>Brief Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Brief Reports</subject></subj-group></article-categories><title-group><article-title>Efficacy and safety of fixed&#x02010;dose combination therapy, alogliptin plus metformin, in <styled-content style="fixed-case">A</styled-content>sian patients with type 2 diabetes: <styled-content style="fixed-case">A</styled-content> phase 3 trial</article-title><alt-title alt-title-type="right-running-head"><styled-content style="fixed-case">JI</styled-content><sc>et al</sc>.</alt-title><alt-title alt-title-type="left-running-head"><styled-content style="fixed-case">JI</styled-content><sc>et al</sc>.</alt-title></title-group><contrib-group><contrib id="dom12875-cr-0001" contrib-type="author" corresp="yes"><name><surname>Ji</surname><given-names>Linong</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1305-1598</contrib-id><address><email>jiln@bjmu.edu.cn</email></address><xref ref-type="aff" rid="dom12875-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12875-cr-0002" contrib-type="author"><name><surname>Li</surname><given-names>Ling</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom12875-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom12875-cr-0003" contrib-type="author"><name><surname>Kuang</surname><given-names>Jian</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom12875-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom12875-cr-0004" contrib-type="author"><name><surname>Yang</surname><given-names>Tao</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom12875-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dom12875-cr-0005" contrib-type="author"><name><surname>Kim</surname><given-names>Dong&#x02010;Jun</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="dom12875-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="dom12875-cr-0006" contrib-type="author"><name><surname>Kadir</surname><given-names>Azidah A.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom12875-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="dom12875-cr-0007" contrib-type="author"><name><surname>Huang</surname><given-names>Chien&#x02010;Ning</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom12875-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="dom12875-cr-0008" contrib-type="author"><name><surname>Lee</surname><given-names>Douglas</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom12875-aff-0008">
<sup>8</sup>
</xref></contrib></contrib-group><aff id="dom12875-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Department of Endocrinology</named-content><institution>Peking University People's Hospital</institution><named-content content-type="city">Beijing</named-content><country country="CN">China</country></aff><aff id="dom12875-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Department of Endocrinology</named-content><institution>Shengjing Hospital of China Medical University</institution><named-content content-type="city">Shenyang</named-content><country country="CN">China</country></aff><aff id="dom12875-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Department of Endocrinology</named-content><institution>Guangdong General Hospital, Guangdong Academy of Medical Sciences</institution><named-content content-type="city">Guangzhou</named-content><country country="CN">China</country></aff><aff id="dom12875-aff-0004"><label><sup>4</sup></label><named-content content-type="organisation-division">Department of Endocrinology</named-content><institution>Jiangsu Province Hospital</institution><named-content content-type="city">Nanjing</named-content><country country="CN">China</country></aff><aff id="dom12875-aff-0005"><label><sup>5</sup></label><named-content content-type="organisation-division">Department of Internal Medicine</named-content><institution>Ilsan Paik Hospital, Inje University</institution><named-content content-type="city">Goyang</named-content><country>Korea</country></aff><aff id="dom12875-aff-0006"><label><sup>6</sup></label><named-content content-type="organisation-division">Department of Family Medicine</named-content><institution>Universiti Sains Malaysia</institution><named-content content-type="city">Kubang Kerian</named-content><country country="MY">Malaysia</country></aff><aff id="dom12875-aff-0007"><label><sup>7</sup></label><named-content content-type="organisation-division">Department of Endocrinology and Metabolism</named-content><institution>Chung Shang Medical University Hospital</institution><named-content content-type="city">Taichung City</named-content><named-content content-type="country-part">Taiwan</named-content><country country="CN">China</country></aff><aff id="dom12875-aff-0008"><label><sup>8</sup></label><institution>Takeda Development Centre Europe, Ltd</institution><named-content content-type="city">London</named-content><country country="GB">United Kingdom</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold> Linong Ji, Department of Endocrinology, People's Hospital of Peking University, Xicheng District, Beijing 100044, China.Email: <email>jiln@bjmu.edu.cn</email></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>2</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2017</year></pub-date><volume>19</volume><issue>5</issue><issue-id pub-id-type="doi">10.1111/dom.2017.19.issue-5</issue-id><fpage>754</fpage><lpage>758</lpage><history><date date-type="received"><day>12</day><month>10</month><year>2016</year></date><date date-type="rev-recd"><day>20</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>29</day><month>12</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. <italic>Diabetes</italic>, Obesity and Metabolism published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-19-754.pdf"/><abstract id="dom12875-abs-0001"><p id="dom12875-para-0001">This study evaluated the efficacy and safety of 26&#x02009;weeks of twice&#x02010;daily (<styled-content style="fixed-case">BID</styled-content>) alogliptin&#x02009;+&#x02009;metformin fixed&#x02010;dose combination (<styled-content style="fixed-case">FDC</styled-content>) therapy in Asian patients with type 2 diabetes. Patients aged 18 to 75&#x02009;years with hemoglobin <styled-content style="fixed-case">A</styled-content>1c (<styled-content style="fixed-case">HbA1c</styled-content>) of 7.5% to 10.0% after &#x02265;2&#x02009;months of diet and exercise and a 4&#x02010;week placebo run&#x02010;in were enrolled. Eligible patients were randomized (1:1:1:1) to placebo, alogliptin 12.5&#x02009;mg <styled-content style="fixed-case">BID</styled-content>, metformin 500&#x02009;mg <styled-content style="fixed-case">BID</styled-content> or alogliptin 12.5&#x02009;mg plus metformin 500&#x02009;mg <styled-content style="fixed-case">FDC BID</styled-content>. The primary endpoint was change in <styled-content style="fixed-case">HbA1c</styled-content> from baseline to end of treatment (<styled-content style="fixed-case">W</styled-content>eek 26). In total, 647 patients were randomized. The least&#x02010;squares mean change in <styled-content style="fixed-case">HbA1c</styled-content> from baseline to <styled-content style="fixed-case">W</styled-content>eek 26 was &#x02212;0.19% with placebo, &#x02212;0.86% with alogliptin, &#x02212;1.04% with metformin and &#x02212;1.53% with alogliptin&#x02009;+&#x02009;metformin <styled-content style="fixed-case">FDC</styled-content>. Alogliptin&#x02009;+&#x02009;metformin <styled-content style="fixed-case">FDC</styled-content> was significantly more effective (<styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.0001) in lowering <styled-content style="fixed-case">HbA1c</styled-content> than either alogliptin or metformin alone. The safety profile of alogliptin&#x02009;+&#x02009;metformin <styled-content style="fixed-case">FDC</styled-content> was similar to that of the individual components alogliptin and metformin. The study demonstrated that treatment with alogliptin&#x02009;+&#x02009;metformin <styled-content style="fixed-case">FDC BID</styled-content> resulted in better glycaemic control than either monotherapy and was well tolerated in Asian patients with type 2 diabetes.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom12875-kwd-0005">alogliptin</kwd><kwd id="dom12875-kwd-0001"><styled-content style="fixed-case">DPP&#x02010;IV</styled-content> inhibitor</kwd><kwd id="dom12875-kwd-0002">glycaemic control</kwd><kwd id="dom12875-kwd-0003">metformin</kwd><kwd id="dom12875-kwd-0004">type 2 diabetes</kwd></kwd-group><funding-group><award-group><funding-source>Takeda Pharmaceutical Company Limited</funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="1"/><page-count count="5"/><word-count count="3313"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom12875</meta-value></custom-meta><custom-meta><meta-name>header-id</meta-name><meta-value>dom12875-hdr-0001</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.9 mode:remove_FC converted:03.05.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="dom12875-cit-1001">
<string-name>
<surname>Ji</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Kuang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>D&#x02010;J</given-names>
</string-name>, <string-name>
<surname>Kadir</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>C&#x02010;N</given-names>
</string-name> and <string-name>
<surname>Lee</surname>
<given-names>D</given-names>
</string-name>. <article-title>Efficacy and safety of fixed&#x02010;dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial</article-title>. <source>Diabetes Obes Metab</source>. <year>2017</year>;<volume>19</volume>:<fpage>754</fpage>&#x02013;<lpage>758</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/dom.12875">https://doi.org/10.1111/dom.12875</ext-link>
<pub-id pub-id-type="pmid">28075066</pub-id></mixed-citation>
</p></notes><notes><fn-group id="dom12875-ntgp-0001a"><fn id="dom12875-note-0003a"><p>
<bold>Funding information</bold> This study was sponsored by Takeda Pharmaceutical Company Limited.</p></fn></fn-group></notes></front><body><sec id="dom12875-sec-0001"><label>1</label><title>INTRODUCTION</title><p id="dom12875-para-0002">The prevalence of diabetes mellitus and suboptimal achievement of glycaemic control is increasing in Asian populations.<xref rid="dom12875-bib-0001" ref-type="ref">1</xref>, <xref rid="dom12875-bib-0002" ref-type="ref">2</xref>, <xref rid="dom12875-bib-0003" ref-type="ref">3</xref> Evidence shows that there may be differences in the pathophysiology of type 2 diabetes across ethnic subgroups, with Asian vs non&#x02010;Asian patients exhibiting a propensity for lower body mass index, a higher proportion of visceral fat and predominant insulin secretory defects.<xref rid="dom12875-bib-0004" ref-type="ref">4</xref>, <xref rid="dom12875-bib-0005" ref-type="ref">5</xref> Although pharmacologic agents are available to patients with type 2 diabetes who fail to achieve sufficient glycaemic control through diet and exercise, many of these agents may cause hypoglycaemia or weight gain.<xref rid="dom12875-bib-0006" ref-type="ref">6</xref>, <xref rid="dom12875-bib-0007" ref-type="ref">7</xref> These adverse events (AEs) often negatively affect treatment adherence and/or long&#x02010;term use. Therefore, there is a need for effective, long&#x02010;term glycaemic control regimens that can be administered safely.</p><p id="dom12875-para-0003">Alogliptin is a potent, highly selective, orally available dipeptidyl peptidase&#x02010;4 (DPP&#x02010;4) inhibitor. Since 2013, alogliptin has been available in the USA and the European Union as monotherapy and as a fixed&#x02010;dose combination (FDC) with metformin. The FDC formulation was developed to improve convenience and, ultimately, patient adherence. Mechanistically, inhibition of DPP&#x02010;4 activity leads to an increase in hormone glucagon&#x02010;like peptide 1 levels, which in turn stimulates glucose&#x02010;dependent insulin secretion from pancreatic &#x003b2;&#x02010;cells.<xref rid="dom12875-bib-0008" ref-type="ref">8</xref> This mechanism of achieving glucose homeostasis is distinct from that of metformin, which is a biguanide that suppresses hepatic glucose release and also induces weight loss via reduced calorie intake.<xref rid="dom12875-bib-0009" ref-type="ref">9</xref>
</p><p id="dom12875-para-0004">Given the complementary mechanisms of action of alogliptin and metformin, and the potential for incrementally improving glycaemic control without exacerbating safety events, there has been interest in the use of this FDC in patients with type 2 diabetes. Phase 3 clinical trials in Asian patients have shown that concomitant administration of alogliptin and metformin is effective and has a safety profile similar to that of the individual components.<xref rid="dom12875-bib-0010" ref-type="ref">10</xref>, <xref rid="dom12875-bib-0011" ref-type="ref">11</xref> The current phase 3 study was designed to evaluate the efficacy and safety of alogliptin 12.5&#x02009;mg plus metformin 500&#x02009;mg FDC BID vs alogliptin or metformin alone in Asian patients with type 2 diabetes who are inadequately controlled with diet and exercise.</p></sec><sec id="dom12875-sec-0002"><label>2</label><title>MATERIALS AND METHODS</title><p id="dom12875-para-0005">This was a phase 3, randomized, double&#x02010;blind, placebo&#x02010;controlled, multicentre study that was conducted at 59 sites in China, Malaysia, Republic of Korea (South Korea) and Taiwan. It was conducted in compliance with the study protocol, the ethical principles originating in the Declaration of Helsinki and the International Conference on Harmonisation of Tripartite Guidelines for Good Clinical Practice. All patients provided written informed consent prior to study procedures.</p><p id="dom12875-para-0006">Patients aged 18 to 75&#x02009;years were eligible if they had an historical diagnosis of type 2 diabetes for which glycaemic control was inadequate (ie, HbA1c of 7.5%&#x02010;10.0% after at least 2&#x02009;months of diet and exercise prior to the screening period). Key exclusion criteria included a significant history of hepatic and cardiovascular disease.</p><p id="dom12875-para-0007">The study consisted of 4 periods: screening (&#x02264;2&#x02009;weeks), placebo run&#x02010;in (4&#x02009;weeks), treatment (26&#x02009;weeks) and follow&#x02010;up (2&#x02009;weeks). Eligible patients had HbA1c of 7.5% to 10.0% and fasting plasma glucose (FPG)&#x02009;&#x02264;&#x02009;275&#x02009;mg/dL (15.27&#x02009;mmol/L) at the Week &#x02212;1 visit of the placebo run&#x02010;in (1&#x02009;week prior to the treatment phase). After stratifying patients by screening HbA1c (&#x0003c;8.5% vs &#x02265;8.5%) and by country, patients were randomized 1:1:1:1: to receive placebo, alogliptin 12.5&#x02009;mg twice&#x02010;daily (BID), metformin 500&#x02009;mg BID or FDC of alogliptin 12.5&#x02009;mg BID plus metformin 500&#x02009;mg BID.</p><p id="dom12875-para-0008">The primary efficacy variable was change from baseline in HbA1c at Week 26 (or early termination) using last observation carried forward. For this variable, 130 patients per treatment group ensured at least 90% power to demonstrate that alogliptin&#x02009;+&#x02009;metformin FDC BID was statistically superior to constituent doses of alogliptin and metformin. This power calculation assumed a treatment effect of 0.45% between the FDC and constituent doses.</p><p id="dom12875-para-0009">The primary efficacy analysis was conducted using the Full Analysis Set (FAS) and an analysis of covariance (ANCOVA) model, with change from baseline in HbA1c at Week 26 (or early termination) as the response variable. Treatment and country were fixed effects and baseline HbA1c was a continuous covariate (Model 1). Each comparison was performed using contrasts derived from Model 1. A supportive analysis was also conducted using Model 1 and the Per&#x02010;Protocol Analysis Set (PPS; ie, patients in the FAS without major protocol deviations).</p><p id="dom12875-para-0010">Changes from baseline in HbA1c and FPG (least&#x02010;squares [LS] means) were summarized at each time point using descriptive statistics. The incidences of hyperglycaemic rescue (for FPG&#x02009;&#x02265;&#x02009;275&#x02009;mg/dL [&#x02265;15.27&#x02009;mmol/L] before Week 12 or HbA1c&#x02009;&#x02265;&#x02009;8.5% and &#x02264;0.5% reduction in HbA1c between Week 12 and the final visit), marked hyperglycaemia (FPG&#x02009;&#x0003e;&#x02009;200&#x02009;mg/dL [11.1&#x02009;mmol/L]) and clinical response were also summarized (frequency and percentage) by treatment group. Continuous secondary endpoints were analysed using an appropriate statistical model with the Model 1 variables. The analysis was carried out using a Cox proportional hazard model, with treatment as an effect, country as a stratification factor and baseline HbA1c as a covariate. For each efficacy variable, the corresponding baseline value for that variable was modeled as a covariate in place of baseline HbA1c. All secondary variables were analysed at the 2&#x02010;sided significance level of 5%.</p><p id="dom12875-para-0011">Treatment&#x02010;emergent AEs (including all events, irrespective of treatment relationship and treatment&#x02010;related AEs), clinical laboratory changes and hypoglycaemic episodes were summarized.</p></sec><sec id="dom12875-sec-0003"><label>3</label><title>RESULTS</title><p id="dom12875-para-0012">Of 1258 screened patients, 647 were randomized to placebo (n&#x02009;=&#x02009;163), alogliptin (n&#x02009;=&#x02009;163), metformin (n&#x02009;=&#x02009;162) or alogliptin&#x02009;+metformin FDC (n&#x02009;=&#x02009;159) and were included in the efficacy and safety populations (Figure S1, File S1). Demographic and clinical characteristics for the randomized population were similar between study groups (Table S1, File S1). Of the 647 treated patients, 511 (n&#x02009;=&#x02009;104, placebo; n&#x02009;=&#x02009;126, alogliptin; n&#x02009;=&#x02009;135, metformin; n&#x02009;=&#x02009;146, alogliptin&#x02009;+metformin FDC) completed the study. The most common reason for study discontinuation was lack of efficacy (n&#x02009;=&#x02009;86 [64.2%] all groups).</p><sec id="dom12875-sec-0004"><label>3.1</label><title>Efficacy</title><p id="dom12875-para-0013">The LS mean change in HbA1c from baseline to end of treatment (Week 26) was &#x02212;0.19% with placebo, &#x02212;0.86% with alogliptin, &#x02212;1.04% with metformin and &#x02212;1.53% with alogliptin&#x02009;+&#x02009;metformin BID (Table <xref rid="dom12875-tbl-0001" ref-type="table-wrap">1</xref>). Changes were significantly greater (<italic>P</italic>&#x02009;&#x0003c;&#x02009;.0001) for alogliptin&#x02009;+&#x02009;metformin FDC vs metformin alone (LS mean difference &#x02212;0.49%; 95% confidence interval [CI] &#x02212;0.700, &#x02212;0.278) and alogliptin alone (LS mean difference &#x02212;0.68%; 95% CI &#x02212;0.889, &#x02212;0.467). Similar results were observed in a supportive analysis using the PPS: alogliptin&#x02009;+&#x02009;metformin FDC BID led to significantly (<italic>P</italic>&#x02009;&#x0003c;&#x02009;.0001) greater reductions from baseline in HbA1c at Week 26 compared with metformin BID or alogliptin BID alone (LS mean differences of &#x02212;0.49% and &#x02212;0.66%, respectively). Significantly greater decreases in mean HbA1c and FPG were observed with alogliptin&#x02009;+&#x02009;metformin FDC vs either alogliptin or metformin alone, beginning with the first on&#x02010;treatment assessment at Week 4 and continuing for all time points throughout the study (<italic>P</italic>&#x02009;&#x0003c;&#x02009;.02 for HbA1c, for all comparisons; <italic>P</italic>&#x02009;&#x02264;&#x02009;.002 for FPG, for all comparisons) (Figure <xref rid="dom12875-fig-0001" ref-type="fig">1</xref>).</p><table-wrap id="dom12875-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Change from baseline in HbA1c (%) to Week 26</p></caption><table frame="hsides" rules="groups"><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th id="dom12875-ent-0001" align="left" valign="bottom" rowspan="1" colspan="1"/><th id="dom12875-ent-0002" align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Placebo (n&#x02009;=&#x02009;161)</bold>
</th><th id="dom12875-ent-0003" align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Metformin (n&#x02009;=&#x02009;161)</bold>
</th><th id="dom12875-ent-0004" align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Alogliptin (n&#x02009;=&#x02009;162)</bold>
</th><th id="dom12875-ent-0005" align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Alogliptin&#x02009;+&#x02009;metformin (n&#x02009;=&#x02009;158)</bold>
</th></tr></thead><tbody valign="top"><tr><td id="dom12875-ent-0006" align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td id="dom12875-ent-0007" align="left" valign="top" rowspan="1" colspan="1"/><td id="dom12875-ent-0008" align="left" valign="top" rowspan="1" colspan="1"/><td id="dom12875-ent-0009" align="left" valign="top" rowspan="1" colspan="1"/><td id="dom12875-ent-0010" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" id="dom12875-ent-0011" align="left" valign="top" rowspan="1" colspan="1">n</td><td id="dom12875-ent-0012" align="left" valign="top" rowspan="1" colspan="1">161</td><td id="dom12875-ent-0013" align="left" valign="top" rowspan="1" colspan="1">161</td><td id="dom12875-ent-0014" align="left" valign="top" rowspan="1" colspan="1">162</td><td id="dom12875-ent-0015" align="left" valign="top" rowspan="1" colspan="1">158</td></tr><tr><td style="padding-left:10%" id="dom12875-ent-0016" align="left" valign="top" rowspan="1" colspan="1">Mean (SD)</td><td id="dom12875-ent-0017" align="left" valign="top" rowspan="1" colspan="1">8.21 (0.77)</td><td id="dom12875-ent-0018" align="left" valign="top" rowspan="1" colspan="1">8.40 (0.77)</td><td id="dom12875-ent-0019" align="left" valign="top" rowspan="1" colspan="1">8.48 (0.71)</td><td id="dom12875-ent-0020" align="left" valign="top" rowspan="1" colspan="1">8.39 (0.81)</td></tr><tr><td id="dom12875-ent-0021" align="left" valign="top" rowspan="1" colspan="1">Change from baseline to Week 26, Model 1<xref ref-type="fn" rid="dom12875-note-0004">
<sup>1</sup>
</xref>
</td><td id="dom12875-ent-0022" align="left" valign="top" rowspan="1" colspan="1"/><td id="dom12875-ent-0023" align="left" valign="top" rowspan="1" colspan="1"/><td id="dom12875-ent-0024" align="left" valign="top" rowspan="1" colspan="1"/><td id="dom12875-ent-0025" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" id="dom12875-ent-0026" align="left" valign="top" rowspan="1" colspan="1">n</td><td id="dom12875-ent-0027" align="left" valign="top" rowspan="1" colspan="1">157</td><td id="dom12875-ent-0028" align="left" valign="top" rowspan="1" colspan="1">160</td><td id="dom12875-ent-0029" align="left" valign="top" rowspan="1" colspan="1">160</td><td id="dom12875-ent-0030" align="left" valign="top" rowspan="1" colspan="1">158</td></tr><tr><td style="padding-left:10%" id="dom12875-ent-0031" align="left" valign="top" rowspan="1" colspan="1">LS mean (SE)</td><td id="dom12875-ent-0032" align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.19</td><td id="dom12875-ent-0033" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.04 (0.11)</td><td id="dom12875-ent-0034" align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.86 (0.11)</td><td id="dom12875-ent-0035" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.53</td></tr><tr><td style="padding-left:10%" id="dom12875-ent-0036" align="left" valign="top" rowspan="1" colspan="1">LS mean difference<xref ref-type="fn" rid="dom12875-note-0005">
<sup>2</sup>
</xref>
</td><td id="dom12875-ent-0037" align="left" valign="top" rowspan="1" colspan="1"/><td id="dom12875-ent-0038" align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.49</td><td id="dom12875-ent-0039" align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.68</td><td id="dom12875-ent-0040" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" id="dom12875-ent-0041" align="left" valign="top" rowspan="1" colspan="1">95% CI</td><td id="dom12875-ent-0042" align="left" valign="top" rowspan="1" colspan="1"/><td id="dom12875-ent-0043" align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.700, &#x02212;0.278</td><td id="dom12875-ent-0044" align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.889, &#x02212;0.467</td><td id="dom12875-ent-0045" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" id="dom12875-ent-0046" align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic>&#x02010;value vs alogliptin&#x02009;+&#x02009;metformin</td><td id="dom12875-ent-0047" align="left" valign="top" rowspan="1" colspan="1"/><td id="dom12875-ent-0048" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.0001</td><td id="dom12875-ent-0049" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.0001</td><td id="dom12875-ent-0050" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="dom12875-ent-0051" align="left" valign="top" rowspan="1" colspan="1">Change from baseline to Week 26, Model 2<xref ref-type="fn" rid="dom12875-note-0006">
<sup>3</sup>
</xref>
</td><td id="dom12875-ent-0052" align="left" valign="top" rowspan="1" colspan="1"/><td id="dom12875-ent-0053" align="left" valign="top" rowspan="1" colspan="1"/><td id="dom12875-ent-0054" align="left" valign="top" rowspan="1" colspan="1"/><td id="dom12875-ent-0055" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" id="dom12875-ent-0056" align="left" valign="top" rowspan="1" colspan="1">N</td><td id="dom12875-ent-0057" align="left" valign="top" rowspan="1" colspan="1">157</td><td id="dom12875-ent-0058" align="left" valign="top" rowspan="1" colspan="1">160</td><td id="dom12875-ent-0059" align="left" valign="top" rowspan="1" colspan="1">160</td><td id="dom12875-ent-0060" align="left" valign="top" rowspan="1" colspan="1">158</td></tr><tr><td style="padding-left:10%" id="dom12875-ent-0061" align="left" valign="top" rowspan="1" colspan="1">LS mean (SE)</td><td id="dom12875-ent-0062" align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.17</td><td id="dom12875-ent-0063" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.17 (0.22)</td><td id="dom12875-ent-0064" align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.74 (0.22)</td><td id="dom12875-ent-0065" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.53</td></tr><tr><td style="padding-left:10%" id="dom12875-ent-0066" align="left" valign="top" rowspan="1" colspan="1">LS mean difference<xref ref-type="fn" rid="dom12875-note-0005">
<sup>2</sup>
</xref>
</td><td id="dom12875-ent-0067" align="left" valign="top" rowspan="1" colspan="1"/><td id="dom12875-ent-0068" align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.36</td><td id="dom12875-ent-0069" align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.78</td><td id="dom12875-ent-0070" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" id="dom12875-ent-0071" align="left" valign="top" rowspan="1" colspan="1">95% CI</td><td id="dom12875-ent-0072" align="left" valign="top" rowspan="1" colspan="1"/><td id="dom12875-ent-0073" align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.793, 0.073</td><td id="dom12875-ent-0074" align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.213, &#x02212;0.353</td><td id="dom12875-ent-0075" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" id="dom12875-ent-0076" align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic>&#x02010;value vs alogliptin&#x02009;+&#x02009;metformin</td><td id="dom12875-ent-0077" align="left" valign="top" rowspan="1" colspan="1"/><td id="dom12875-ent-0078" align="left" valign="top" rowspan="1" colspan="1">0.103</td><td id="dom12875-ent-0079" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12875-ent-0080" align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="dom12875-note-0003"><p>Abbreviations: <styled-content style="fixed-case">CI</styled-content>, confidence interval; <styled-content style="fixed-case">HbA1c</styled-content>, haemoglobin <styled-content style="fixed-case">A</styled-content>1c; <styled-content style="fixed-case">LS</styled-content>, least&#x02010;squares; <styled-content style="fixed-case">SD</styled-content>, standard deviation; <styled-content style="fixed-case">SE</styled-content>, standard error.</p></fn><fn id="dom12875-note-0004"><label><sup>1</sup></label><p>Covariates were treatment, country, baseline <styled-content style="fixed-case">HbA1c</styled-content>.</p></fn><fn id="dom12875-note-0005"><label><sup>2</sup></label><p>Vs alogliptin&#x02009;+&#x02009;metformin.</p></fn><fn id="dom12875-note-0006"><label><sup>3</sup></label><p>Covariates were treatment, country, baseline <styled-content style="fixed-case">HbA1c</styled-content>, treatment by baseline <styled-content style="fixed-case">HbA1c</styled-content> and treatment by country interaction.</p></fn></table-wrap-foot></table-wrap><fig fig-type="Figure" xml:lang="en" id="dom12875-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Analysis of adjusted mean change from baseline in (<styled-content style="fixed-case">A</styled-content>) haemoglobin <styled-content style="fixed-case">A</styled-content>1c (<styled-content style="fixed-case">HbA1c</styled-content>; %) and (<styled-content style="fixed-case">B</styled-content>) fasting plasma glucose (<styled-content style="fixed-case">FPG</styled-content>; mmol/<styled-content style="fixed-case">L</styled-content>) to <styled-content style="fixed-case">W</styled-content>eek 26. <styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.02 for <styled-content style="fixed-case">HbA1c</styled-content>, for all comparisons; <styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x02264;&#x02009;.002 for <styled-content style="fixed-case">FPG</styled-content>, for all comparisons. <styled-content style="fixed-case">BID</styled-content>, twice daily; <styled-content style="fixed-case">FDC</styled-content>, fixed&#x02010;dose combination.</p></caption><graphic id="nlm-graphic-1" xlink:href="DOM-19-754-g001"/></fig><p id="dom12875-para-0014">A lower proportion of patients in the alogliptin&#x02009;+&#x02009;metformin FDC group required hyperglycaemic rescue by Week 26 (4.4%) compared with the proportion of patients in the placebo group (25.5%), alogliptin (14.8%) and metformin (8.7%) groups; this difference was significant as compared with the alogliptin group (<italic>P</italic>&#x02009;=&#x02009;.002). A similar trend was observed for marked hyperglycaemia (<italic>P</italic>&#x02009;=&#x02009;.040 vs alogliptin). For time to hyperglycaemic rescue, both placebo and metformin had a significantly lower adjusted risk ratio vs alogliptin&#x02009;+&#x02009;metformin FDC (<italic>P</italic>&#x02009;&#x0003c;&#x02009;.0001 and <italic>P</italic>&#x02009;=&#x02009;.002, respectively) (Figure S2, File S1). A higher proportion of patients in the alogliptin&#x02009;+&#x02009;metformin FDC group had HbA1c clinical response at Week 26 as compared with patients in the other 3 treatment groups (Table S2, File S1).</p></sec><sec id="dom12875-sec-0005"><label>3.2</label><title>Safety</title><p id="dom12875-para-0015">The overall frequency of treatment&#x02010;emergent AEs was similar for the 4 treatment groups: 48.4% for placebo, 46.3% for alogliptin, 47.2% for metformin and 45.6% for alogliptin&#x02009;+&#x02009;metformin FDC (Table S3, File S1). Across all treatment groups, upper respiratory tract infection was the most common AE, and the only AE with &#x02265;5% incidence (range 4.9%&#x02010;6.8%). The overall frequency of serious AEs (SAEs) ranged from 2.5% to 3.1%. Two SAEs were considered to be related to treatment: moderate gastroenteritis (1 event; placebo) that resolved in 8 days, and moderate unstable angina (1 event; alogliptin&#x02009;+&#x02009;metformin FDC) that resolved in 9 days. Overall, 19 patients (3.0%) experienced 23 hypoglycaemic events during the study, 6.2% in the metformin group, 3.8% in the alogliptin&#x02009;+&#x02009;metformin FDC group, 1.2% in the alogliptin group and 0.6% in the placebo group.</p></sec></sec><sec id="dom12875-sec-0006"><label>4</label><title>DISCUSSION</title><p id="dom12875-para-0016">This phase 3 study demonstrated significantly greater reductions in HbA1c over 26&#x02009;weeks with alogliptin&#x02009;+&#x02009;metformin FDC vs alogliptin or metformin. The advantages of the FDC regimen in reducing HbA1c (primary endpoint) and FPG (secondary endpoint) were evident at Week 4, with sustained effects throughout the study. By Week 26, the rate of achieving clinical response measures was higher and the rate of hyperglycaemic rescue or marked hyperglycaemia was lower with alogliptin&#x02009;+&#x02009;metformin FDC.</p><p id="dom12875-para-0017">Overall, alogliptin&#x02009;+&#x02009;metformin FDC demonstrated a favourable safety profile. The incidence of hypoglycaemia (6.2%) was highest in the metformin&#x02010;alone group, which is difficult to explain, as the incidence of hypoglycaemia in the alogliptin&#x02009;+&#x02009;metformin FDC group was lower (3.8%). The overall incidence of AEs and SAEs did not differ with alogliptin&#x02009;+&#x02009;metformin FDC vs each monotherapy. This finding is consistent with data from prior phase 3 clinical trials that tested concomitant alogliptin&#x02009;+&#x02009;metformin in Asian patients.<xref rid="dom12875-bib-0010" ref-type="ref">10</xref>, <xref rid="dom12875-bib-0011" ref-type="ref">11</xref>, <xref rid="dom12875-bib-0012" ref-type="ref">12</xref> In addition, a meta&#x02010;analysis of various DDP&#x02010;4 inhibitors plus metformin as initial therapy revealed no increase in the risk of hypoglycaemia or prolonged gastrointestinal complaints relative to metformin monotherapy.<xref rid="dom12875-bib-0013" ref-type="ref">13</xref>
</p><p id="dom12875-para-0018">The efficacy and safety of alogliptin&#x02009;+&#x02009;metformin FDC demonstrated in this study is of particular importance because of potential differences in the pathophysiology of type 2 diabetes in Asians compared with other populations. Furthermore, there are multiple reasons why alogliptin&#x02009;+&#x02009;metformin FDC represents an important addition to the glycaemic&#x02010;lowering armamentarium in Asia. First, patients are predisposed to multiple comorbidities and polypharmacy, and improving medication adherence is associated with better glycaemic control.<xref rid="dom12875-bib-0014" ref-type="ref">14</xref> Second, the FDC incorporates 2 commonly prescribed classes of a type 2 diabetes agent with different mechanisms of action. Metformin is recommended in international diabetes guidelines as first&#x02010;line treatment of patients with type 2 diabetes,<xref rid="dom12875-bib-0015" ref-type="ref">15</xref> while DPP&#x02010;4 inhibitors are recommended in the second&#x02010;line setting. Similar recommendations have been made in Asian diabetes guidelines, such as those published by the Chinese Diabetes Society.<xref rid="dom12875-bib-0016" ref-type="ref">16</xref> Last, the ENDURE study, where alogliptin was added to stable doses of metformin, demonstrated the sustainability of glycaemic control.<xref rid="dom12875-bib-0017" ref-type="ref">17</xref>
</p><p id="dom12875-para-0019">One limitation of the study is its relatively short duration, which provided no insight into the durability of HbA1c lowering, long&#x02010;term tolerability or adherence. However, the durability of the treatment effect was addressed in the ENDURE study.<xref rid="dom12875-bib-0017" ref-type="ref">17</xref> Additionally, our study was conducted in eastern Asian countries and employed extensive eligibility criteria, which precludes the extrapolation of results to the entire type 2 diabetes population.</p><p id="dom12875-para-0020">In conclusion, alogliptin&#x02009;+&#x02009;metformin FDC BID resulted in better glycaemic control as compared with alogliptin or metformin alone in Asian patients with type 2 diabetes who were inadequately controlled with diet and exercise. The safety profile of the combination was comparable to that of the individual components.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="dom12875-supitem-0001"><caption><p>
<bold>Appendix S1.</bold> Eligibility criteria, patient demographic and clinical characteristics, incidence of HbA1c clinical response at week 26, adverse events, patient disposition, and time to hyperglycemic rescue</p></caption><media xlink:href="DOM-19-754-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dom12875-sec-0007"><title>ACKNOWLEDGMENTS</title><p id="dom12875-para-0021">Medical writing support was provided by BlueMomentum, a division of Ashfield Healthcare Communications (a UDG Healthcare plc company), and was funded by Takeda Pharmaceutical Company Limited.</p></ack><ack id="dom12875-sec-0007a"><title>Conflict of interest</title><p id="dom12875-para-0021a">L.J. has received research grants and consulting fees from Takeda. L.L. has no relevant conflicts of interest to disclose. J.K. has received research grants and consulting fees from Takeda. T.Y. has no relevant conflicts of interest to disclose. D.K. has received research grants and consulting fees from Takeda. A.A.K. has received research grants and consulting fees from Takeda. C.H. has received research grants and consulting fees from Takeda. D.L. reports employment with Takeda.</p></ack><ack id="dom12875-sec-0007b"><title>Author contributions</title><p id="dom12875-para-0021b">L.J. contributed to the study design, study conduct/data collection, and writing of the manuscript. L.L. contributed to study conduct/data collection and the writing of the manuscript. J.K. contributed to study conduct/data collection and the writing of the manuscript. T.Y. contributed to study conduct/data collection and the writing of the manuscript. D.K. contributed to study design, study conduct/data collection, and the writing of the manuscript. A.A.K. contributed to study conduct/data collection and the writing of the manuscript. C.H. contributed to study design, study conduct/data collection, and the writing of the manuscript. D.L. contributed to study conduct/data collection, data analysis, and the writing of the manuscript.</p></ack><ref-list content-type="cited-references" id="dom12875-bibl-0001"><title>REFERENCES</title><ref id="dom12875-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dom12875-cit-0001">
<string-name>
<surname>Xu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>J</given-names>
</string-name>, et al; <collab collab-type="authors" id="dom12875-gp-0001">2010 China Noncommunicable Disease Surveillance Group</collab>
. <article-title>Prevalence and control of diabetes in Chinese adults</article-title>. <source>JAMA</source>. <year>2013</year>;<volume>310</volume>:<fpage>948</fpage>&#x02010;<lpage>959</lpage>.<pub-id pub-id-type="pmid">24002281</pub-id></mixed-citation></ref><ref id="dom12875-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dom12875-cit-0002">
<string-name>
<surname>Fung</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Wan</surname>
<given-names>EY</given-names>
</string-name>, <string-name>
<surname>Jiao</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Lam</surname>
<given-names>CL</given-names>
</string-name>. <article-title>Five&#x02010;year change of clinical and complications profile of diabetic patients under primary care: a population&#x02010;based longitudinal study on 127,977 diabetic patients</article-title>. <source>Diabetol Metab Syndr</source>. <year>2015</year>;<volume>7</volume>:<fpage>79</fpage>.<pub-id pub-id-type="pmid">26388950</pub-id></mixed-citation></ref><ref id="dom12875-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom12875-cit-0003">
<string-name>
<surname>Yu</surname>
<given-names>NC</given-names>
</string-name>, <string-name>
<surname>Su</surname>
<given-names>HY</given-names>
</string-name>, <string-name>
<surname>Chiou</surname>
<given-names>ST</given-names>
</string-name>, et al. <article-title>Trends of ABC control 2006&#x02010;2011: a National Survey of Diabetes Health Promotion Institutes in Taiwan</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2013</year>;<volume>99</volume>:<fpage>112</fpage>&#x02010;<lpage>119</lpage>.<pub-id pub-id-type="pmid">23265923</pub-id></mixed-citation></ref><ref id="dom12875-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dom12875-cit-0004">
<string-name>
<surname>Eastwood</surname>
<given-names>SV</given-names>
</string-name>, <string-name>
<surname>Tillin</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Dehbi</surname>
<given-names>HM</given-names>
</string-name>, et al. <article-title>Ethnic differences in associations between fat deposition and incident diabetes and underlying mechanisms: the SABRE study</article-title>. <source>Obesity (Silver Spring)</source>. <year>2015</year>;<volume>23</volume>:<fpage>699</fpage>&#x02010;<lpage>706</lpage>.<pub-id pub-id-type="pmid">25645144</pub-id></mixed-citation></ref><ref id="dom12875-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dom12875-cit-0005">
<string-name>
<surname>Ma</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>JC</given-names>
</string-name>. <article-title>Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States</article-title>. <source>Ann N Y Acad Sci</source>. <year>2013</year>;<volume>1281</volume>:<fpage>64</fpage>&#x02010;<lpage>91</lpage>.<pub-id pub-id-type="pmid">23551121</pub-id></mixed-citation></ref><ref id="dom12875-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dom12875-cit-0006">
<string-name>
<surname>Mearns</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Sobieraj</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>CM</given-names>
</string-name>, et al. <article-title>Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta&#x02010;analysis</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>:<fpage>e0125879</fpage>.<pub-id pub-id-type="pmid">25919293</pub-id></mixed-citation></ref><ref id="dom12875-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom12875-cit-0007">
<string-name>
<surname>Bodmer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Meier</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kr&#x000e4;henb&#x000fc;hl</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Jick</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Meier</surname>
<given-names>CR</given-names>
</string-name>. <article-title>Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case&#x02010;control analysis</article-title>. <source>Diabetes Care</source>. <year>2008</year>;<volume>31</volume>:<fpage>2086</fpage>&#x02010;<lpage>2091</lpage>.<pub-id pub-id-type="pmid">18782901</pub-id></mixed-citation></ref><ref id="dom12875-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom12875-cit-0008">
<string-name>
<surname>Seino</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Fukushima</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yabe</surname>
<given-names>D</given-names>
</string-name>. <article-title>GIP and GLP&#x02010;1, the two incretin hormones: similarities and differences</article-title>. <source>J Diabetes Investig</source>. <year>2010</year>;<volume>1</volume>:<fpage>8</fpage>&#x02010;<lpage>23</lpage>.</mixed-citation></ref><ref id="dom12875-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dom12875-cit-0009">
<string-name>
<surname>Lee</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Morley</surname>
<given-names>JE</given-names>
</string-name>. <article-title>Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non&#x02010;insulin&#x02010;dependent diabetes</article-title>. <source>Obes Res</source>. <year>1998</year>;<volume>6</volume>:<fpage>47</fpage>&#x02010;<lpage>53</lpage>.<pub-id pub-id-type="pmid">9526970</pub-id></mixed-citation></ref><ref id="dom12875-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dom12875-cit-0010">
<string-name>
<surname>Pan</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Zeng</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Efficacy and safety of alogliptin in treatment of type 2 diabetes mellitus: a multicenter, randomized, double&#x02010;blind, placebo&#x02010;controlled phase III clinical trial in mainland China</article-title>. <source>Zhonghua Nei Ke Za Zhi</source>. <year>2015</year>;<volume>54</volume>:<fpage>949</fpage>&#x02010;<lpage>953</lpage>.<pub-id pub-id-type="pmid">26759214</pub-id></mixed-citation></ref><ref id="dom12875-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom12875-cit-0011">
<string-name>
<surname>Seino</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Miyata</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hiroi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hirayama</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kaku</surname>
<given-names>K</given-names>
</string-name>. <article-title>Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double&#x02010;blind, placebo&#x02010;controlled trial with an open&#x02010;label, long&#x02010;term extension study</article-title>. <source>Diabetes Obes Metab</source>. <year>2012</year>;<volume>14</volume>:<fpage>927</fpage>&#x02010;<lpage>936</lpage>.<pub-id pub-id-type="pmid">22583697</pub-id></mixed-citation></ref><ref id="dom12875-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom12875-cit-0012">
<string-name>
<surname>Pan</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Ji</surname>
<given-names>Q</given-names>
</string-name>, et al. <article-title>Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: a multicentre, randomized, double&#x02010;blind, placebo&#x02010;controlled, phase 3 study in mainland China, Taiwan, and Hong Kong</article-title>. <source>J Diabetes</source>. <year>2016</year>. doi:10.1111/1753&#x02010;0407.12425.</mixed-citation></ref><ref id="dom12875-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dom12875-cit-0013">
<string-name>
<surname>Wu</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>C</given-names>
</string-name>. <article-title>Efficacy and safety of dipeptidyl peptidase&#x02010;4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta&#x02010;analysis</article-title>. <source>Diabetes Obes Metab</source>. <year>2014</year>;<volume>16</volume>:<fpage>30</fpage>&#x02010;<lpage>37</lpage>.<pub-id pub-id-type="pmid">23803146</pub-id></mixed-citation></ref><ref id="dom12875-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="dom12875-cit-0014">
<string-name>
<surname>Rozenfeld</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hunt</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Plauschinat</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>KS</given-names>
</string-name>. <article-title>Oral antidiabetic medication adherence and glycemic control in managed care</article-title>. <source>Am J Manag Care</source>. <year>2008</year>;<volume>14</volume>:<fpage>71</fpage>&#x02010;<lpage>75</lpage>.<pub-id pub-id-type="pmid">18269302</pub-id></mixed-citation></ref><ref id="dom12875-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dom12875-cit-0015">
<string-name>
<surname>Inzucchi</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Bergenstal</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Buse</surname>
<given-names>JB</given-names>
</string-name>, et al. <article-title>Management of hyperglycemia in type 2 diabetes, 2015: a patient&#x02010;centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes</article-title>. <source>Diabetes Care</source>. <year>2015</year>;<volume>38</volume>:<fpage>140</fpage>&#x02010;<lpage>149</lpage>.<pub-id pub-id-type="pmid">25538310</pub-id></mixed-citation></ref><ref id="dom12875-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="dom12875-cit-0016">
<string-name>
<surname>Weng</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ji</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Jia</surname>
<given-names>W</given-names>
</string-name>, et al; <collab collab-type="authors" id="dom12875-gp-0002">Chinese Diabetes Society</collab>
. <article-title>Standards of care for type 2 diabetes in China</article-title>. <source>Diabetes Metab Res Rev</source>. <year>2016</year>;<volume>32</volume>:<fpage>442</fpage>&#x02010;<lpage>458</lpage>.<pub-id pub-id-type="pmid">27464265</pub-id></mixed-citation></ref><ref id="dom12875-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="dom12875-cit-0017">
<string-name>
<surname>Del Prato</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Camisasca</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Fleck</surname>
<given-names>P</given-names>
</string-name>. <article-title>Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2&#x02010;year study</article-title>. <source>Diabetes Obes Metab</source>. <year>2014</year>;<volume>16</volume>:<fpage>1239</fpage>&#x02010;<lpage>1246</lpage>.<pub-id pub-id-type="pmid">25132212</pub-id></mixed-citation></ref></ref-list></back></article>